Implements a partially optimized Bayesian single-arm phase II design for a binary efficacy endpoint with efficacy and futility stopping. The design searches candidate response-count boundaries and, subject to prespecified error constraints, selects the design that minimizes the grey-zone at the final look. The package creates decision tables and evaluates operating characteristics by exact trial-path enumeration or Monte Carlo simulation.
pob2ef implements a partially optimized Bayesian single-arm phase II design
for a binary efficacy endpoint with efficacy and futility stopping. The design
searches candidate response-count boundaries and, subject to prespecified error
constraints, selects the design that minimizes the grey-zone at the final look.
The package creates decision tables and evaluates operating characteristics by
exact trial-path enumeration or Monte Carlo simulation.
After CRAN publication, install the released package with:
install.packages("pob2ef")
To install the development version from GitHub:
remotes::install_github("clinrfnl/pob2ef")
Let $\theta$ denote the true response rate, with unacceptable benchmark $p_0$ and clinically desirable target $p_1 > p_0$. At an analysis after $n$ evaluable participants, the design declares:
The boundary family is
$$ C_F(n) = \lambda_1(n/N)^\gamma, \qquad C_E(n) = 1 - \lambda_2(n/N)^\eta. $$
The tuning parameters satisfy
$$ 0 < \lambda_1 \leq 0.5, \qquad 0 < \lambda_2 < 0.5, \qquad \gamma, \eta \geq 0. $$
The design is calibrated to constrain superiority probability at $p_0$ by $\alpha$ and futility probability at $p_1$ by $\beta$. Among feasible boundary settings, it minimizes the final grey-zone probability at $p_1$, then expected sample size at $p_0$.
pob2ef is a distinct method. Related published methods include BOP2 and
BOP2-FE:
Zhou, H., Lee, J. J., and Yuan, Y. (2017). BOP2: Bayesian optimal design for phase II clinical trials with simple and complex endpoints. Statistics in Medicine, 36(21), 3302-3314. https://doi.org/10.1002/sim.7338
Xu, X., Hashimoto, A., Yimer, B. B., and Takeda, K. (2025). BOP2-FE: Bayesian optimal phase II design with futility and efficacy-stopping boundaries. Journal of Biopharmaceutical Statistics. https://doi.org/10.1080/10543406.2025.2558142
library(pob2ef)
design <- select_design(
n_max = 20,
looks = c(10, 20),
p0 = 0.20,
p1 = 0.40,
alpha = 0.10,
beta = 0.20,
lambda1_grid = c(0.10, 0.30, 0.50),
lambda2_grid = c(0.05, 0.10, 0.20),
gamma_grid = 0:2,
eta_grid = 0:2
)
design$selected
decision_table(design)
plot_decision_boundaries(design)
simulation <- simulate_design(
design,
true_rates = c(0.20, 0.30, 0.40),
n_sim = 1000,
seed = 2026
)
simulation$results
plot_operating_characteristics(
simulation,
metric = "superiority_probability"
)